Harborview Advisors’s Pfizer PFE Stock Holding History

Harborview Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$368K	Buy	8,557 +1,006	+13%	+$44.6K	0.21%	79
2021 Q2	$296K	Buy	7,551 +8	+0.1%	+$311	0.17%	86
2021 Q1	$273K	Buy	7,543 +8	+0.1%	+$284	0.17%	84
2020 Q4	$277K	Sell	7,535 -400	-5%	-$14.7K	0.19%	80
2020 Q3	$276K	Buy	7,935 +9	+0.1%	+$316	0.21%	78
2020 Q2	$246K	Buy	7,926 +8	+0.1%	+$272	0.2%	77
2020 Q1	$245K	Buy	7,918 +1,115	+16%	+$38K	0.24%	68
2019 Q4	$253K	Sell	6,803 -98	-1%	-$3.49K	0.19%	74
2019 Q3	$235K	Buy	+6,901	New	+$251K	0.19%	74

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Harborview Advisors's PFE Position: Q3 2021 in Review

Harborview Advisors increased its Pfizer (PFE) stake by 13% in Q3 2021, buying an estimated $44.6K and bringing the position to 8,557 shares worth $368K. The position accounts for 0.21% of the portfolio, ranked #79.

Harborview Advisors first reported a position in PFE in Q3 2019 and has held it in 9 quarters since. 2,804 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

Harborview Advisors held 8,557 shares of Pfizer worth $368K as of Q3 2021.
Harborview Advisors bought 1,006 Pfizer shares in Q3 2021, an estimated $44.6K.
Pfizer made up 0.21% of Harborview Advisors's portfolio in Q3 2021, its #79 holding.
Harborview Advisors first reported a position in Pfizer in Q3 2019 and has held it in 9 quarters since.
2,804 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on Harborview Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.